Elevation Oncology Inc. (NASDAQ:ELEV)’s traded shares stood at 1.01 million during the last session. At the close of trading, the stock’s price was $2.55, to imply an increase of 8.51% or $0.2 in intraday trading. The ELEV share’s 52-week high remains $4.61, putting it -80.78% down since that peak but still an impressive 71.76% since price per share fell to its 52-week low of $0.72. The company has a valuation of $65.87M, with an average of 2.37 million shares in intraday trading volume over the past 10 days and average of 488.70K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Elevation Oncology Inc. (ELEV), translating to a mean rating of 2.40. Of 3 analyst(s) looking at the stock, 0 analyst(s) give ELEV a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.78.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Elevation Oncology Inc. (NASDAQ:ELEV) trade information
After registering a 8.51% upside in the last session, Elevation Oncology Inc. (ELEV) has traded red over the past five days. The stock hit a weekly high of 2.58 this Friday, 03/17/23, jumping 8.51% in its intraday price action. The 5-day price performance for the stock is 112.50%, and 160.20% over 30 days. With these gigs, the year-to-date price performance is 168.42%. Short interest in Elevation Oncology Inc. (NASDAQ:ELEV) saw shorts transact 33700.0 shares and set a 0.24 days time to cover.
Analysts on Wall Street suggest a consensus price target of $2.50, implying a decrease of -2.0% to the stock’s current value. The extremes give us $1.00 and $4.00 for target low and target high price respectively. As such, ELEV has been trading -56.86% off suggested target high and 60.78% from its likely low.
Elevation Oncology Inc. (ELEV) estimates and forecasts
Looking at statistics comparing Elevation Oncology Inc. share performance against respective industry, we note that the company has underperformed competitors. Elevation Oncology Inc. (ELEV) shares are 104.00% up over the last 6 months, with its year-to-date growth rate lower than industry average at -126.83% against 9.60%. Revenue is forecast to shrink -90.20% this quarter before jumping 10.80% for the next one.
ELEV Dividends
Elevation Oncology Inc. has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Elevation Oncology Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Elevation Oncology Inc. (NASDAQ:ELEV)’s Major holders
Elevation Oncology Inc. insiders hold 2.18% of total outstanding shares, with institutional holders owning 71.11% of the shares at 72.70% float percentage. In total, 71.11% institutions holds shares in the company, led by Aisling Capital Management LP. As of Sep 29, 2022, the company held over 2.83 million shares (or 12.17% of shares), all amounting to roughly $3.2 million.
The next major institution holding the largest number of shares is Qiming U.s. Ventures Management, Llc with 2.37 million shares, or about 10.17% of shares outstanding. As of the market price on Dec 30, 2022, these shares were worth $2.25 million.
We also have Vanguard Total Stock Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund as the top two Mutual Funds with the largest holdings of the Elevation Oncology Inc. (ELEV) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 0.27 million shares. This is just over 1.14% of the total shares, with a market valuation of $0.3 million. Data from the same date shows that the other fund manager holds a little less at 0.13 million, or 0.55% of the shares, all valued at about 0.14 million.
